Sera Reports Significant Growth in PreTRM Test Volume and Medicaid Expansion

Sera (SERA) reported strong third-quarter 2026 results, highlighted by a fivefold increase in test volume for its PreTRM blood test compared to the first quarter of 2026. The company's growth is being driven by expanding Medicaid coverage in key states like Florida and Illinois, which allows for high-volume, reimbursed patient access. Management is focusing on scaling commercial adoption through physician education and pilot programs with major national health plans to secure private insurance coverage. With $72.8 million in cash providing a runway into fiscal year 2029, the company aims to maintain flat or declining operating expenses in 2027 while expanding its sales team and pursuing international expansion.

By The Motley Fool Team · Motley Fool ·

Sera Reports Significant Growth in PreTRM Test Volume and Medicaid Expansion

Tickers: $SERA

Topics: commercial scaling maternal health diagnostics Medicaid expansion test volume growth

Read the full article at Motley Fool

More World news